As the estrogen patch shortage continues, these women are meeting with the FDA
A group of women is meeting with FDA officials to discuss the ongoing estrogen patch shortage, which has affected nearly half of women on hormone replacement therapy. The shortage has caused some women to stop treatment, ration patches, or switch to more expensive alternatives.
Physicians are concerned that a lack of access to estrogen patches, a common medication for menopause, could undo years of progress in improving care for women. A group of women, led by the founders of Midi Health, met with FDA officials on May 6 to discuss solutions. Estrogen patches have been in short supply since the start of the year, with almost half of women on hormone replacement therapy having difficulty filling their prescriptions. A Midi survey of over 8,000 women found that one in 10 stopped treatment due to the shortage, and nine in 10 were not confident they could fill their next prescription. The FDA has been talking with the five biggest patch manufacturers to ensure they are running at capacity. Estrogen patches help protect against osteoporosis and alleviate symptoms such as night sweats and irritability.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.